Efficacy of adjuvant CDK4/6 inhibitors in Hormone Receptor-positive breast cancer: a systematic review and meta-analysis.
Yakup ErgünMutlu DoganGokhan UcarPınar KaracinCengiz KaracinPublished in: Expert opinion on pharmacotherapy (2023)
Addition of CDK4/6 inhibitors to standard ET in the adjuvant treatment of HR-positive/HER2-negative early-stage BC improves iDFS.